|
US4647580A
(en)
|
1985-07-18 |
1987-03-03 |
Syntex (U.S.A.) Inc. |
Treatment of Alzheimer's disease
|
|
US5043345A
(en)
|
1989-02-22 |
1991-08-27 |
Novo Nordisk A/S |
Piperidine compounds and their preparation and use
|
|
US5852029A
(en)
|
1990-04-10 |
1998-12-22 |
Israel Institute For Biological Research |
Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
|
|
US5480651A
(en)
|
1992-03-16 |
1996-01-02 |
Regents Of The University Of California |
Composition and method for treating nicotine craving in smoking cessation
|
|
DE69430816T2
(de)
*
|
1993-08-19 |
2002-12-19 |
Novo Nordisk A/S, Bagsvaerd |
Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
|
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
|
DE19612504C2
(de)
|
1996-03-29 |
2003-10-23 |
Boehringer Ingelheim Kg |
Neue Wirkstoffkompositionen
|
|
GB9612710D0
(en)
|
1996-06-18 |
1996-08-21 |
Pfizer Ltd |
Method of treatment
|
|
EP0821956A1
(en)
|
1996-08-01 |
1998-02-04 |
Eli Lilly And Company |
Method for treating disruptive behavior disorders
|
|
EP0821957A3
(en)
|
1996-08-01 |
1998-04-22 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
|
|
EP0821959A3
(en)
|
1996-08-01 |
1998-09-16 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
|
|
EP0821954A1
(en)
|
1996-08-01 |
1998-02-04 |
Eli Lilly And Company |
Method for treating mental retardation
|
|
EP0821958A3
(en)
|
1996-08-01 |
1998-07-08 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
|
|
DK0821955T3
(da)
|
1996-08-01 |
2002-03-18 |
Lilly Co Eli |
Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
|
|
AU5716898A
(en)
|
1997-01-08 |
1998-08-03 |
Warner-Lambert Company |
Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
|
|
PL346247A1
(en)
|
1998-08-18 |
2002-01-28 |
Ucb Sa |
Muscarinic agonists and antagonists
|
|
CN1396829A
(zh)
|
2000-02-24 |
2003-02-12 |
法玛西雅厄普约翰美国公司 |
新的药物联合形式
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
AU2001268055A1
(en)
|
2000-06-30 |
2002-01-14 |
Eli Lilly And Company |
Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
|
|
EP1352659A4
(en)
|
2000-12-22 |
2004-06-30 |
Takeda Chemical Industries Ltd |
COMBINATION DRUGS
|
|
EP1357900A2
(en)
|
2001-01-30 |
2003-11-05 |
Board of Regents, The University of Texas System |
Process for production of nanoparticles and microparticles by spray freezing into liquid
|
|
US20040023951A1
(en)
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
|
WO2003030818A2
(en)
|
2001-10-05 |
2003-04-17 |
Pichit Suvanprakorn |
Active agents using liposome beads
|
|
US20040224012A1
(en)
|
2001-10-05 |
2004-11-11 |
Pichit Suvanprakorn |
Topical application and methods for administration of active agents using liposome macro-beads
|
|
US6887866B2
(en)
*
|
2002-01-25 |
2005-05-03 |
Theravance, Inc. |
Short-acting sedative hypnotic agents for anesthesia and sedation
|
|
WO2004060347A2
(en)
|
2002-09-03 |
2004-07-22 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
|
MXPA04010921A
(es)
|
2002-05-03 |
2005-05-27 |
Israel Inst Biolog Res |
Metodos y composiciones para el tratamietno de trastornos del sistema nervioso central y periferico y compuestos novedosos utiles para los mismos.
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
US20050250767A1
(en)
|
2003-01-23 |
2005-11-10 |
Weiner David M |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
US20050085463A1
(en)
|
2003-01-23 |
2005-04-21 |
Weiner David M. |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
GB0307860D0
(en)
|
2003-04-04 |
2003-05-14 |
Novartis Ag |
Organic compounds
|
|
WO2005044262A1
(en)
*
|
2003-10-29 |
2005-05-19 |
Wyeth |
Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
|
|
ES2359375T3
(es)
|
2003-11-04 |
2011-05-20 |
Supernus Pharmaceuticals, Inc. |
Formas de dosificación de dosis única diaria de trospio.
|
|
US7763609B2
(en)
|
2003-12-15 |
2010-07-27 |
Schering Corporation |
Heterocyclic aspartyl protease inhibitors
|
|
KR101157881B1
(ko)
|
2003-12-22 |
2012-07-06 |
아카디아 파마슈티칼스 인코포레이티드 |
무스카린 작용제로서의 아미노 치환된 디아릴［ａ,ｄ］사이클로헵텐 유사체, 및 신경정신 질환의 치료 방법
|
|
US9016221B2
(en)
|
2004-02-17 |
2015-04-28 |
University Of Florida Research Foundation, Inc. |
Surface topographies for non-toxic bioadhesion control
|
|
ES2257152B1
(es)
|
2004-05-31 |
2007-07-01 |
Laboratorios Almirall S.A. |
Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
|
|
CA2582385A1
(en)
|
2004-06-18 |
2005-12-18 |
Neurochem (International) Limited |
Therapeutic formulations for the treatment of beta-amyloid related diseases
|
|
GB0428170D0
(en)
|
2004-12-23 |
2005-01-26 |
Biopartners Ltd |
Mono and Combination Therapy
|
|
GB0428180D0
(en)
|
2004-12-23 |
2005-01-26 |
Biopartners Ltd |
Combination therapy
|
|
US20060183733A1
(en)
|
2005-02-11 |
2006-08-17 |
Stephen Wills |
Treating microvasculature diseases with acetyl cholinesterase inhibitors
|
|
JP4732769B2
(ja)
|
2005-03-04 |
2011-07-27 |
富士フイルム株式会社 |
内視鏡装置
|
|
TW200800959A
(en)
|
2005-06-10 |
2008-01-01 |
Wyeth Corp |
Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
|
|
KR20080025079A
(ko)
|
2005-06-14 |
2008-03-19 |
쉐링 코포레이션 |
아스파르틸 프로테아제 억제제
|
|
US7390816B2
(en)
|
2005-06-21 |
2008-06-24 |
Bridge Pharma, Inc. |
Methods for treating urinary incontinence in patients suffering from memory disorders
|
|
EP1928437A2
(en)
|
2005-08-26 |
2008-06-11 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
CN103142586A
(zh)
|
2005-09-02 |
2013-06-12 |
塞拉维达公司 |
治疗疾病的疗法
|
|
US8158152B2
(en)
|
2005-11-18 |
2012-04-17 |
Scidose Llc |
Lyophilization process and products obtained thereby
|
|
GB0607949D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607952D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res Ltd |
Novel treatment
|
|
GB0607946D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
TW200811105A
(en)
|
2006-04-25 |
2008-03-01 |
Theravance Inc |
Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
ES2336275T3
(es)
|
2006-05-04 |
2010-04-09 |
Solvay Pharmaceuticals B.V. |
Agonistas muscarinicos para tratar trastornos del control de impulsos.
|
|
US7905852B2
(en)
|
2006-05-16 |
2011-03-15 |
Barbara Jennings-Spring |
Skin-contacting-adhesive free dressing
|
|
US8097633B2
(en)
|
2006-11-15 |
2012-01-17 |
Rich Steven A |
Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
|
|
US20100015184A1
(en)
|
2006-12-13 |
2010-01-21 |
Tuel Stephen M |
Methods of Making Pharmaceutical Components for Customized Drug Products
|
|
GB0702385D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
New combination
|
|
GB0702416D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
New combination
|
|
GB0702456D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
New combination
|
|
GB0702457D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
New combination 666
|
|
GB0703999D0
(en)
|
2007-03-01 |
2007-04-11 |
Astrazeneca Ab |
New combination 667
|
|
AU2008233232A1
(en)
|
2007-03-29 |
2008-10-09 |
Merck Sharp & Dohme Corp. |
Combination therapy for the treatment-of lower urinary tract symptoms
|
|
WO2009003724A1
(en)
*
|
2007-07-03 |
2009-01-08 |
Synthon B.V. |
Tolterodine bead
|
|
WO2009036243A1
(en)
|
2007-09-12 |
2009-03-19 |
Glaxo Group Limited |
Novel combination of therapeutic agents
|
|
WO2009037503A2
(en)
|
2007-09-18 |
2009-03-26 |
Astrazeneca Ab |
New combination - 012 for the treatment of respiratory diseases
|
|
NO2200610T3
(enExample)
|
2007-09-21 |
2018-06-09 |
|
|
|
CN102014877B
(zh)
|
2008-01-25 |
2017-06-06 |
格吕伦塔尔有限公司 |
药物剂型
|
|
MX344177B
(es)
|
2008-03-27 |
2016-12-08 |
Chase Pharmaceuticals Corp |
Uso y composicion para tratar la demencia.
|
|
US20110119259A1
(en)
|
2008-04-24 |
2011-05-19 |
Trustees Of Boston University |
Network biology approach for identifying targets for combination therapies
|
|
GB0822077D0
(en)
|
2008-12-03 |
2009-01-07 |
Minster Res Ltd |
Novel treatments
|
|
AU2010221133A1
(en)
|
2009-03-05 |
2011-09-22 |
Mithridion, Inc. |
Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
|
|
US10265311B2
(en)
*
|
2009-07-22 |
2019-04-23 |
PureTech Health LLC |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
EP3061821B1
(en)
|
2009-07-22 |
2019-07-10 |
Puretech Health LLC |
Compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
CA2786716A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Mithridion, Inc. |
Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
|
|
SG174658A1
(en)
|
2010-04-01 |
2011-10-28 |
Theravida Inc |
Pharmaceutical formulations for the treatment of overactive bladder
|
|
WO2012033956A1
(en)
|
2010-09-08 |
2012-03-15 |
Mithridion, Inc. |
Cognition enhancing compounds and compositions, methods of making, and methods of treating
|
|
US20120289529A1
(en)
*
|
2011-05-10 |
2012-11-15 |
Theravida, Inc. |
Combinations of trospium and salivary stimulants for the treatment of overactive bladder
|
|
CA2835293C
(en)
|
2011-06-08 |
2020-08-18 |
Sti Pharma, Llc |
Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
|
|
US20130289019A1
(en)
|
2012-04-26 |
2013-10-31 |
Amazing Grace, Inc. |
Methods of treating behaviorial and/or mental disorders
|
|
CN104768540A
(zh)
|
2012-09-05 |
2015-07-08 |
才思制药公司 |
抗胆碱能神经保护组合物和方法
|
|
EP3265067A4
(en)
|
2015-03-06 |
2018-09-12 |
Chase Pharmaceuticals Corporation |
Oxybutynin-xanomeline transdermal therapeutic system combinations
|
|
US10307409B2
(en)
*
|
2015-03-06 |
2019-06-04 |
Chase Pharmaceuticals Corporation |
Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
|
|
US20180050018A1
(en)
|
2015-03-06 |
2018-02-22 |
Chase Pharmaceuticals Corporation |
Peripheral-anticholinergic muscarinic agonist combination
|
|
JP6566254B2
(ja)
|
2015-08-21 |
2019-08-28 |
セイコープレシジョン株式会社 |
フォーカルプレーンシャッタおよび光学機器
|
|
HK1258048A1
(zh)
|
2015-09-01 |
2019-11-01 |
First Wave Bio, Inc. |
用於治疗与异常炎症反应相关的病症的方法和组合物
|
|
EP3347012A4
(en)
|
2015-09-11 |
2019-04-17 |
Chase Pharmaceuticals Corporation |
MUSCARIN COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDER OF THE CENTRAL NERVOUS SYSTEM
|
|
CL2018000559A1
(es)
|
2015-10-14 |
2018-08-17 |
First Wave Bio Inc |
Métodos y composiciones para tratar condiciones asociadas con respuestas inflamatorias anormales
|
|
CN108697688A
(zh)
|
2016-01-20 |
2018-10-23 |
塞拉维达公司 |
用于治疗多汗症的方法和组合物
|
|
WO2017147104A1
(en)
|
2016-02-24 |
2017-08-31 |
Chase Pharmaceuticals Corporation |
Muscarinic m2-antagonist combinations
|
|
MX391629B
(es)
|
2018-09-28 |
2025-03-21 |
Karuna Therapeutics Inc |
Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico
|
|
US20210145804A1
(en)
|
2019-11-18 |
2021-05-20 |
Karuna Therapeutics, Inc. |
Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
|
|
CN120478350A
(zh)
|
2019-11-18 |
2025-08-15 |
卡鲁娜治疗学有限公司 |
用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
|
|
JP2024507367A
(ja)
|
2021-02-24 |
2024-02-19 |
カルナ セラピューティックス，インコーポレイテッド |
ムスカリン受容体活性化によって改善される障害を処置するための方法
|
|
US20220370454A1
(en)
|
2021-05-18 |
2022-11-24 |
Karuna Therapeutics, Inc. |
Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics
|